Molina Healthcare had its Relative Strength (RS) Rating upgraded from 65 to 73 Tuesday — a welcome improvement, but still short of the 80 or higher score you look for.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if Molina Healthcare can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
The IBD 50 stock is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could ignite a new run.
Molina Healthcare reported 15% earnings growth last quarter. Revenue rose 16%.
The company holds the No. 1 rank among its peers in the Medical-Managed Care industry group. Cigna Group and Alignment Healthcare are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
